entertainment -WSS

entertainment

author：fashion 2025-10-01 05:39:43 - browse：9

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： RaDonda Vaught links Vanderbilt hospital issues to patient death

leisure time

WSS

Male and female sex labels in research insufficient, scientists say

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Medicare Advantage overpayments discussion gets experts fired up

RaDonda Vaught links Vanderbilt hospital issues to patient death

Physician assistants need a new name. Here's what it should be

Merck to acquire Harpoon Therapeutics for $680 million

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

How to save PrEP access — and even expand it

In shift, Texas to cover initial consult for Afghan baby's gene therapy

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Physician assistants need a new name. Here's what it should be

BioMarin wins approval for gene therapy to treat hemophilia A

Allen Institute goes after foundational questions, CEO Costa says

The cancer drug shortage isn’t new — and neither are the solutions

Boston Scientific acquires urology company Axonics for $3.7 billion

Virginia high school admissions case could be legal follow

Boston's new lab space is opening empty

entertainment

Life science postdocs should get big pay hike, NIH panel says

Profiling embryos to choose those with higher IQs is almost a reality

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

President Biden's budget: Here's what you might have missed

Change Healthcare outage fallout shows need for new oversight

How to save health care price transparency rules

explore

leisure time

hotspot

explore